Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Patent Blue | The risk or severity of hypotension can be increased when Patent Blue is combined with Lypressin. |
| Thyrotropin alfa | Thyrotropin alfa may increase the vasoconstricting activities of Lypressin. |
| Liothyronine | Liothyronine may increase the vasoconstricting activities of Lypressin. |
| Levothyroxine | Levothyroxine may increase the vasoconstricting activities of Lypressin. |
| Liotrix | Liotrix may increase the vasoconstricting activities of Lypressin. |
| Tiratricol | Tiratricol may increase the vasoconstricting activities of Lypressin. |
| Thyroid, porcine | Thyroid, porcine may increase the vasoconstricting activities of Lypressin. |
| Lidocaine | The risk or severity of hypertension can be increased when Lypressin is combined with Lidocaine. |
| Oxytocin | The risk or severity of hypertension can be increased when Lypressin is combined with Oxytocin. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Lypressin is combined with Chloroprocaine. |